Kratos Research Labs

KRL10 RUO launch access: documentation-led small-order review, product docs, and gated catalog access after RUO acknowledgement. Send KRL10 review request. Research use only; not for human or veterinary use.

Tag: obesity

  • What Does the Published Research Say About AOD-9604?

    Research Context

    The packet includes: (a) limited direct human data indicating favorable safety/tolerability for AOD-9604 in a phase II clinical setting and FDA PCAC materials outlining clinical/regulatory context [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891; fda:pcac-aod-9604-183584]; (b) review literature on therapeutic peptides and obesity pharmacotherapy that provides field context but not AOD-9604–specific clinical outcomes [pubmed:41490200; pubmed:16931496; pubmed:17971763; pubmed:22435392; pubmed:16625817; pubmed:15134286]; and (c) preclinical studies (animal/in vitro) plus analytical/anti-doping detection literature for AOD-9604 and related growth-hormone fragments [pubmed:11673763; pubmed:11713213; pubmed:11146367; pubmed:25208511; pubmed:24124033; pubmed:26213263].

    Key Takeaway

    In this packet, direct human evidence for AOD-9604 is limited to a phase II safety/tolerability signal; the provided citations do not establish human efficacy outcomes.

    Direct Answer

    • A phase II clinical study reported favorable safety and tolerability for AOD-9604; conclusions should remain limited to the specific population and endpoints studied (safety/tolerability-focused) [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891].
    • Reviews frame the broader peptide and obesity-therapy landscape but are not substitutes for primary human outcome evidence and are not specific proof of AOD-9604 clinical benefit [pubmed:41490200; pubmed:16931496; pubmed:17971763; pubmed:22435392; pubmed:16625817; pubmed:15134286].
    • Preclinical mouse and in vitro studies report metabolic/lipolytic or characterization findings; these do not establish human outcomes [pubmed:11673763; pubmed:11713213; pubmed:11146367; pubmed:25208511]. In some rodent work, related GH fragments were studied that may not be identical to AOD-9604.
    • Analytical studies address detection and assay interference; they inform testing context, not clinical efficacy or safety [pubmed:24124033; pubmed:26213263; pubmed:25208511].

    Direct human evidence

    • A phase II clinical trial in an obesity-related context reported a favorable safety/tolerability signal for AOD-9604; the evaluated endpoints focused on safety/tolerability rather than efficacy [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891].
    • Guardrail: Do not infer efficacy or generalized safety beyond the specific population and endpoints evaluated in the cited human study and FDA PCAC review materials [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891; fda:pcac-aod-9604-183584].

    Review literature (field context; not proof of outcomes)

    • Reviews cover therapeutic peptides (including an orthopaedics-focused overview) and obesity pharmacotherapy. These provide mechanistic/translational context but do not establish AOD-9604 clinical outcomes [pubmed:41490200; pubmed:16931496; pubmed:17971763; pubmed:22435392; pubmed:16625817].
    • Classification note: pubmed:15134286 is treated here as contextual/non-primary; it should not be used to claim human outcomes for AOD-9604 [pubmed:15134286].

    Preclinical and mechanistic evidence

    • Sequence/characterization: AOD-9604 corresponds to the C-terminal fragment of human growth hormone (amino acids 177–191) with an additional N-terminal tyrosine [pubmed:25208511; pubmed:11146367].
    • Animal/in vitro findings (model scope reflected by titles):
    • Obese mice: chronic treatment with human GH or a modified C-terminal fragment increased fat oxidation and reduced weight [pubmed:11673763].
    • Obese and β3-adrenergic receptor knockout mice: human GH and the lipolytic fragment AOD-9604 affected lipid metabolism after chronic treatment [pubmed:11713213].
    • In vitro/biochemical: metabolic studies of a synthetic lipolytic domain (AOD-9604) [pubmed:11146367].
    • In vitro/analytical: detection and in vitro metabolism of AOD-9604 [pubmed:25208511].
    • Translation caveat: Some rodent data involve fragments related to, but not necessarily identical with, AOD-9604. These results are hypothesis-generating and should not be presented as established human outcomes [pubmed:11673763; pubmed:11713213; pubmed:11146367; pubmed:25208511].

    Analytical detection and anti-doping context (not clinical outcomes)

    • AOD-9604 does not influence the WADA hGH isoform immunoassay; this finding is assay-specific and should not be generalized to all GH-related assays [pubmed:24124033].
    • Mass-spectrometry reviews and detection/metabolism studies describe analytical identification of peptides/AOD-9604; these do not inform clinical benefit [pubmed:26213263; pubmed:25208511].

    What is not established (limitations from the packet)

    • Broad claims of clinical efficacy beyond the specific human endpoints studied are not supported by the provided citations in this packet [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891; fda:pcac-aod-9604-183584].
    • Dosing guidance and generalized safety outside the studied setting are not justified by the packet [fda:pcac-aod-9604-183584; crossref:10.2165/00128413-200313770-00018].
    • Animal/in vitro findings should not be reframed as proven clinical efficacy; mechanistic plausibility alone does not establish clinical utility [pubmed:11673763; pubmed:11713213; pubmed:11146367; pubmed:25208511].

    FAQ

    • What human outcomes are supported for AOD-9604?
    • In this packet, a phase II study reported favorable safety/tolerability; no human efficacy outcomes are established in the provided citations [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891; fda:pcac-aod-9604-183584].
    • Does AOD-9604 reduce fat or weight in humans?
    • Not established in this packet. Rodent studies reported metabolic/weight effects, but these are not evidence of human outcomes [pubmed:11673763; pubmed:11713213].
    • What exactly is AOD-9604?
    • A peptide corresponding to hGH residues 177–191 with an added N-terminal tyrosine, characterized in preclinical/analytical work [pubmed:25208511; pubmed:11146367].
    • Does AOD-9604 interfere with growth hormone anti-doping tests?
    • One study found it does not influence the WADA hGH isoform immunoassay; this is assay-specific and does not generalize to all assays. Detection by mass spectrometry is described in analytical literature [pubmed:24124033; pubmed:26213263; pubmed:25208511].
    • Are there dosing or broad safety recommendations?
    • No. The packet does not justify dosing guidance or generalized safety beyond the cited human study context [fda:pcac-aod-9604-183584; crossref:10.2165/00128413-200313770-00018].

    References

    • [crossref:10.2165/00128413-200313770-00018] The anti-obesity drug AOD-9604* has demonstrated favourable safety and tolerability in a phase II clinical trial. https://doi.org/10.2165/00128413-200313770-00018
    • [fda:pcac-aod-9604-183891] FDA PCAC meeting material: AOD-9604 clinical and regulatory context. https://www.fda.gov/media/183891/download
    • [fda:pcac-aod-9604-183584] FDA PCAC support document: AOD-9604 literature and clinical-study review. https://www.fda.gov/media/183584/download
    • [pubmed:41490200] Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. https://pubmed.ncbi.nlm.nih.gov/41490200/
    • [pubmed:15134286] AOD-9604 Metabolic. https://pubmed.ncbi.nlm.nih.gov/15134286/
    • [pubmed:25208511] Detection and in vitro metabolism of AOD9604. https://pubmed.ncbi.nlm.nih.gov/25208511/
    • [pubmed:26213263] Human sports drug testing by mass spectrometry. https://pubmed.ncbi.nlm.nih.gov/26213263/
    • [pubmed:11713213] The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. https://pubmed.ncbi.nlm.nih.gov/11713213/
    • [pubmed:16931496] Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. https://pubmed.ncbi.nlm.nih.gov/16931496/
    • [pubmed:17971763] [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. https://pubmed.ncbi.nlm.nih.gov/17971763/
    • [pubmed:11673763] Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. https://pubmed.ncbi.nlm.nih.gov/11673763/
    • [pubmed:22435392] Current updates in the medical management of obesity. https://pubmed.ncbi.nlm.nih.gov/22435392/
    • [pubmed:16625817] Obesity drugs in clinical development. https://pubmed.ncbi.nlm.nih.gov/16625817/
    • [pubmed:11146367] Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. https://pubmed.ncbi.nlm.nih.gov/11146367/
    • [pubmed:24124033] AOD-9604 does not influence the WADA hGH isoform immunoassay. https://pubmed.ncbi.nlm.nih.gov/24124033/

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About Semaglutide?

    Research Context

    The synthesis packet contains 12 PubMed-indexed sources: eight primary human studies and four reviews; no preclinical sources. Conclusions should remain anchored to the specific populations, endpoints, and formulations explicitly studied. Review literature can frame context but does not substitute for primary human outcome data.

    Direct Answer

    Published human randomized trials in this packet most robustly report weight-management outcomes primarily in adults with overweight or obesity without diabetes, using both subcutaneous and oral formulations [pubmed:35015037][pubmed:37385278][pubmed:38330988]. Additional human research addresses functional capacity (walking outcomes) in people with symptomatic peripheral artery disease and type 2 diabetes [pubmed:40169145]. Cardiovascular outcomes and metabolic dysfunction–associated steatohepatitis (MASH) are represented here only by trial design/baseline publications, without reported outcomes [pubmed:36945734][pubmed:39412509]. Systematic reviews synthesize efficacy in obesity without diabetes; a safety-focused review addresses semaglutide more broadly and should not be over-narrowed to obesity-only contexts [pubmed:36578889][pubmed:38679221][pubmed:34942372][pubmed:34305810].

    Human Clinical Evidence

    • Weight management in adults (primarily without diabetes)
    • STEP 8: Weekly subcutaneous semaglutide versus daily liraglutide; primary outcomes centered on body-weight change in adults with overweight or obesity without diabetes [pubmed:35015037].
    • OASIS 1: Oral semaglutide 50 mg once daily versus placebo; weight outcomes in adults with overweight or obesity (the title does not specify diabetes status) [pubmed:37385278].
    • STEP 7: Once-weekly semaglutide 2.4 mg versus placebo; weight outcomes in a predominantly East Asian population with overweight or obesity [pubmed:38330988].
    • Functional capacity in peripheral artery disease with type 2 diabetes
    • STRIDE (phase 3b): Double-blind, randomized, placebo-controlled trial evaluating walking capacity endpoints in people with symptomatic peripheral artery disease and type 2 diabetes [pubmed:40169145].
    • Cardiovascular outcomes (design/baseline only in this packet)
    • SOUL: Design and baseline characteristics for a randomized cardiovascular outcomes trial of oral semaglutide in people with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease; no outcomes are reported in the materials provided here [pubmed:36945734].
    • MASH (design/baseline only in this packet)
    • ESSENCE (phase 3): Baseline characteristics and trial design evaluating semaglutide 2.4 mg in participants with MASH; no outcomes are reported in the materials provided here [pubmed:39412509].
    • Comparator and combination contexts (do not imply monotherapy outcomes)
    • Tirzepatide comparator trial (phase 1): Multicenter, randomized, double-blind study comparing tirzepatide with placebo or semaglutide on islet function and insulin sensitivity in adults with type 2 diabetes; this context does not establish semaglutide monotherapy efficacy beyond its role as a comparator [pubmed:35468322].
    • Cagrilintide–semaglutide combination: Study in adults with overweight or obesity and type 2 diabetes; as a combination therapy, it does not isolate semaglutide monotherapy effects [pubmed:40544432].

    Outcome evidence is strongest for weight-management trials primarily in adults without diabetes. Cardiovascular and MASH questions are represented here by design/baseline papers only and should not be interpreted as established clinical outcomes within this packet.

    Review Literature

    • Systematic review and meta-analysis on efficacy and safety for weight loss in obesity without diabetes [pubmed:36578889].
    • Systematic review and meta-analysis on long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes across randomized controlled trials [pubmed:38679221].
    • Review on semaglutide for the treatment of obesity [pubmed:34942372].
    • Safety-focused review addressing semaglutide broadly (not limited to obesity without diabetes) [pubmed:34305810].

    These reviews contextualize mechanisms, efficacy, and safety but remain limited by the included primary RCTs and do not extend findings to unstudied populations, endpoints, or formulations beyond those tested.

    Preclinical and Mechanistic Evidence

    • No preclinical or purely mechanistic sources are included in the packet.

    What Is Not Established

    • Cardiovascular outcomes and MASH efficacy: Only trial designs/baseline characteristics are included (SOUL, ESSENCE); no outcome data are provided here and efficacy should not be inferred.
    • Generalized dosing and safety extrapolation beyond the studied contexts.
    • Anti-aging or broad peptide claims unsupported by direct human outcomes in this packet.
    • Cross-formulation or cross-population generalizations not tested in the cited studies.

    References

    • [pubmed:35015037] Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/35015037/
    • [pubmed:37385278] Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. https://pubmed.ncbi.nlm.nih.gov/37385278/
    • [pubmed:38330988] Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. https://pubmed.ncbi.nlm.nih.gov/38330988/
    • [pubmed:40169145] Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. https://pubmed.ncbi.nlm.nih.gov/40169145/
    • [pubmed:36945734] Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. https://pubmed.ncbi.nlm.nih.gov/36945734/
    • [pubmed:39412509] Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. https://pubmed.ncbi.nlm.nih.gov/39412509/
    • [pubmed:35468322] Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. https://pubmed.ncbi.nlm.nih.gov/35468322/
    • [pubmed:40544432] Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/40544432/
    • [pubmed:36578889] Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. https://pubmed.ncbi.nlm.nih.gov/36578889/
    • [pubmed:38679221] Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. https://pubmed.ncbi.nlm.nih.gov/38679221/
    • [pubmed:34942372] Semaglutide for the treatment of obesity. https://pubmed.ncbi.nlm.nih.gov/34942372/
    • [pubmed:34305810] Safety of Semaglutide. https://pubmed.ncbi.nlm.nih.gov/34305810/

    Research-use-only catalog access

    KRL product pages are gated and require age and research-use-only acknowledgement before prices, cart, or checkout are available.

    Access catalog path
    Browse technical product pages

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About Tirzepatide?

    Research Context

    The supplied synthesis packet includes twelve human clinical sources, zero review sources, and zero preclinical sources. The citations therefore represent human clinical studies but are not uniformly interventional outcome reports; study designs vary by citation. The packet explicitly cautions that conclusions should remain anchored to the specific populations, endpoints, and disease contexts studied in those human studies [pubmed:38078870, pubmed:35658024, pubmed:34170647, pubmed:39536238, pubmed:37758044].

    The packet assigns high confidence to the presence of direct human evidence and medium confidence to any generalization across populations or endpoints [pubmed:38078870, pubmed:35658024, pubmed:34170647, pubmed:39536238, pubmed:37758044]. It contains no review or preclinical sources.

    Direct Answer

    Published research on tirzepatide in this packet consists of human clinical studies across obesity, type 2 diabetes, and select comorbid populations (e.g., obstructive sleep apnea with obesity, heart failure with preserved ejection fraction with obesity, and metabolic dysfunction–associated steatohepatitis). The strongest conclusions should remain tied to the specific populations and endpoints of each study. Notably, at least one cardiovascular citation (SURPASS-CVOT design/baseline characteristics) is a design/baseline paper rather than an outcomes report [pubmed:37758044]. No dosing guidance, broad safety generalizations, or mechanistic claims are supported by this packet alone.

    Human Clinical Evidence by Topic (based on citation titles)

    • Obesity and weight maintenance:
    • Continued treatment for maintenance of weight reduction in adults with obesity (SURMOUNT-4) [pubmed:38078870].
    • Tirzepatide once weekly for the treatment of obesity [pubmed:35658024].
    • Obesity treatment in people with type 2 diabetes (SURMOUNT-2) [pubmed:37385275].
    • Obesity treatment and diabetes prevention [pubmed:39536238].
    • Type 2 diabetes and cardiovascular context:
    • Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes [pubmed:34170647].
    • SURPASS-CVOT design and baseline characteristics comparing tirzepatide and dulaglutide for major adverse cardiovascular events; this is a design/baseline report and does not provide outcomes [pubmed:37758044].
    • Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes [pubmed:41406444].
    • Obesity-related comorbidities:
    • Tirzepatide for obstructive sleep apnea and obesity [pubmed:38912654].
    • Tirzepatide for heart failure with preserved ejection fraction and obesity [pubmed:39555826].
    • Metabolic liver disease:
    • Tirzepatide for metabolic dysfunction–associated steatohepatitis with liver fibrosis [pubmed:38856224].
    • Comparative pharmacotherapy for overweight or obesity:
    • Semaglutide versus tirzepatide for weight loss in adults with overweight or obesity [pubmed:38976257, pubmed:40353578].

    Study Design Notes and Limits

    • Study designs vary across citations (e.g., randomized trials, design/baseline reports, and other human clinical study types). Conclusions should be interpreted within each study’s design constraints; the packet does not specify uniform RCT outcomes for all entries [pubmed:37758044].
    • The SURPASS-CVOT citation provided is a design/baseline characteristics paper and should not be interpreted as reporting cardiovascular outcomes [pubmed:37758044].
    • Several citations focus on comorbid subpopulations (e.g., type 2 diabetes with obesity, heart failure with preserved ejection fraction with obesity, obstructive sleep apnea with obesity), which limits generalizability to broader populations.
    • The packet does not reproduce quantitative efficacy or safety data. Absence of such data here does not imply absence in the primary publications; readers should consult the cited papers for detailed results and safety findings.

    What Is Not Established by This Packet

    • Dosing, comprehensive safety profiles, and off-label extrapolation are not established by the supplied materials and remain incompletely addressed.
    • Anti-aging or broad metabolic enhancement claims are not supported.
    • Mechanistic plausibility alone does not establish clinical utility; mechanistic or animal-based inferences are outside the scope of this packet.
    • Broad generalization beyond the studied populations and endpoints is not warranted.

    Evidence Not Included in the Packet

    • Review literature: none included.
    • Preclinical/mechanistic studies: none included.

    References

    • [pubmed:38078870] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/38078870/
    • [pubmed:35658024] Tirzepatide Once Weekly for the Treatment of Obesity. https://pubmed.ncbi.nlm.nih.gov/35658024/
    • [pubmed:34170647] Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/34170647/
    • [pubmed:39536238] Tirzepatide for Obesity Treatment and Diabetes Prevention. https://pubmed.ncbi.nlm.nih.gov/39536238/
    • [pubmed:37758044] Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. https://pubmed.ncbi.nlm.nih.gov/37758044/
    • [pubmed:38912654] Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. https://pubmed.ncbi.nlm.nih.gov/38912654/
    • [pubmed:39555826] Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. https://pubmed.ncbi.nlm.nih.gov/39555826/
    • [pubmed:37385275] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. https://pubmed.ncbi.nlm.nih.gov/37385275/
    • [pubmed:38976257] Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. https://pubmed.ncbi.nlm.nih.gov/38976257/
    • [pubmed:40353578] Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. https://pubmed.ncbi.nlm.nih.gov/40353578/
    • [pubmed:38856224] Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. https://pubmed.ncbi.nlm.nih.gov/38856224/
    • [pubmed:41406444] Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/41406444/

    Research-use-only catalog access

    KRL product pages are gated and require age and research-use-only acknowledgement before prices, cart, or checkout are available.

    Access catalog path
    Browse technical product pages

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About Retatrutide?

    Research Context

    Retatrutide (LY3437943) is a triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon receptors [pubmed:37366315][pubmed:37385280][pubmed:38858523][pubmed:41090431]. The literature base includes: (1) primary human phase 2 trials, (2) review articles offering class-level and mechanistic context, and (3) translational/preclinical work spanning discovery to early clinical proof-of-concept. This article separates those layers and anchors conclusions to the human data.

    Direct Answer

    Direct human evidence for retatrutide comes from randomized phase 2 trials in adults with obesity, in people with type 2 diabetes, and in metabolic dysfunction-associated steatotic liver disease (MASLD) [pubmed:37366315][pubmed:37385280][pubmed:38858523]. Registrational TRIUMPH trial designs for obesity, obstructive sleep apnea (OSA), and knee osteoarthritis are published and ongoing, with no outcomes reported yet [pubmed:41090431]. Review literature provides mechanistic and class-level context for incretin-based therapies but does not substitute for retatrutide-specific outcome data [pubmed:38843460][pubmed:38302593][pubmed:39952695][pubmed:38687506][pubmed:40563436][pubmed:39761578][pubmed:38511400]. Class-level GLP-1 receptor agonist cardiorenal benefits have not been demonstrated for retatrutide.

    Direct Human Evidence

    • Evidence scope and populations. Randomized phase 2 trials have evaluated retatrutide in: adults with obesity [pubmed:37366315]; people with type 2 diabetes [pubmed:37385280]; and individuals with MASLD [pubmed:38858523].
    • Endpoints studied. The obesity trial assessed body-weight outcomes [pubmed:37366315]. The type 2 diabetes trial (double-blind, placebo- and active-controlled) focused on glycemic control [pubmed:37385280]. The MASLD trial examined hepatic outcomes (e.g., imaging/biomarker-based) [pubmed:38858523].
    • Ongoing registrational program. TRIUMPH registrational trial designs for obesity, OSA, and knee osteoarthritis are published, but outcomes have not been reported; these designs do not imply established efficacy for OSA or knee osteoarthritis [pubmed:41090431].

    Taken together, the strongest conclusions should remain anchored to the studied populations, endpoints, and disease contexts from these phase 2 trials [pubmed:37366315][pubmed:37385280][pubmed:38858523][pubmed:41090431].

    Review Literature and Translational Context

    Review articles frame the broader incretin landscape, including GLP-1 receptor agonist development for type 2 diabetes and obesity and established cardiorenal benefits in select populations for some GLP-1 agents; these class-level findings have not been demonstrated for retatrutide [pubmed:38843460]. Additional reviews describe the obesity pharmacotherapy pipeline [pubmed:38302593][pubmed:39952695], interactions between incretin-based therapy and resistance exercise on body composition [pubmed:38687506], and position retatrutide within the evolving treatment landscape [pubmed:40563436]. Systematic review data on GLP-1 receptor agonists for weight management in adults without diabetes and foundational insights into gut hormone biology add further context, without serving as retatrutide-specific outcome evidence [pubmed:39761578][pubmed:38511400].

    Review literature can inform mechanisms and translational plausibility but does not replace primary human outcomes for retatrutide itself [pubmed:38843460][pubmed:38302593][pubmed:39952695][pubmed:38687506][pubmed:40563436].

    Preclinical and Mechanistic Evidence

    A translational report describes the discovery of LY3437943 through early clinical proof-of-concept, providing mechanistic rationale for targeting GIP, GLP-1, and glucagon receptors [pubmed:35985340]. While informative, this discovery-to-PoC continuum does not establish definitive clinical outcomes beyond the dedicated phase 2 trials, and animal or in vitro signals should not be presented as established human effects [pubmed:35985340].

    What Is Not Established

    • Dosing specifics, comprehensive safety profiles, and long-term outcomes remain incompletely addressed in the available literature.
    • Class-level GLP-1 receptor agonist cardiorenal benefits should not be generalized to retatrutide absent direct evidence [pubmed:38843460].
    • TRIUMPH registrational trials for obesity, OSA, and knee osteoarthritis are ongoing; no outcomes have been published, and efficacy in OSA or knee osteoarthritis should not be inferred from trial designs [pubmed:41090431].
    • Translational and preclinical findings, including early PoC signals, are not substitutes for established clinical outcomes [pubmed:35985340].

    References

    • [pubmed:37366315] Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.
    • [pubmed:37385280] Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial.
    • [pubmed:38858523] Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial.
    • [pubmed:41090431] Retatrutide for obesity, obstructive sleep apnea, and knee osteoarthritis: TRIUMPH registrational trial designs.
    • [pubmed:38843460] Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
    • [pubmed:38302593] What is the pipeline for future medications for obesity?
    • [pubmed:39952695] Emerging pharmacotherapies for obesity: A systematic review.
    • [pubmed:38687506] Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
    • [pubmed:40563436] Retatrutide—A Game Changer in Obesity Pharmacotherapy. (review context only)
    • [pubmed:39761578] Efficacy and Safety of GLP-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review.
    • [pubmed:38511400] Gut hormones and appetite regulation.
    • [pubmed:35985340] LY3437943, a novel triple GCG, GIP, and GLP-1 receptor agonist: From discovery to early clinical proof of concept.

    Research-use-only catalog access

    KRL product pages are gated and require age and research-use-only acknowledgement before prices, cart, or checkout are available.

    Access catalog path
    Browse technical product pages

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides